









The U.S. National Academy of Medicine (NAM) International Health Policy Fellowship Seminar

23 February 2022 (Wed) 9:30 a.m. – 11:00 a.m. (Hong Kong Time) / 8:30 p.m. – 10:00 p.m. on 22 February 2022 (Eastern Standard Time)

Online via Zoom

Abstracts & Biographies of Speaker/Discussion Panel/Distinguished Guests

Speaker

Prof. Roger CHUNG

"Global Coordination on Vaccines to Counter Pandemic Threats: Key Messages and Implications for the Hong Kong Special Administration Region"

Over two years after COVID-19 was declared a public health emergency of international concern, the world is still grappling with the pandemic, amidst emerging variants and increasing hospitalizations. The cost of being unprepared for a global pandemic is now clear, and the world cannot afford to be caught unprepared again.

The <u>Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response Initiative</u> at the U.S. National Academy of Medicine (NAM) explored how the scientific and technological breakthroughs achieved during COVID-19 could inform and advance future pandemic and seasonal influenza vaccine preparedness and response efforts. As a result, a consensus study titled <u>Countering the Pandemic Threat Through Global Coordination on Vaccines: The Influenza Imperative</u> was released in November 2021 as one of the four reports from the initiative.

Prof. Roger Chung, inaugural NAM International Health Policy Fellow, served as a consultant on this report. In this talk, he will summarize the report's recommendations, which outline how to operationalize lessons learned from COVID-19; potential integrated solutions to prepare for the future potential of pandemic influenza and other pandemics; and how to ensure equitable access to vaccines globally. He will then discuss about the implications of these recommendations to Hong Kong SAR, China

Roger Chung is the inaugural National Academy of Medicine International Health Policy Fellow (2018–22), studying the issues of health equity and social determinants of healthy longevity. A social epidemiologist by training, his research uses the lens of biomedical ethics and justice to examine the social determinants of health and health inequalities. He is currently examining social determinants such as poverty, deprivation, socioeconomic disadvantage, environmental and housing factors, and migrant status. He is also particularly interested in the health of the vulnerable populations, including migrant workers and rare disease patients. Additionally, he is conducting research on aging-related issues, such as multimorbidity and long-term/end-of-life care. Collectively, the purpose of his research is to inform health services and public policy, domestically and beyond. He is currently an Assistant Professor of the School of Public Health and Primary Care of the Chinese University of Hong Kong. He is also the Associate Director of the CUHK Centre for Bioethics and the Institute of Health Equity.

Discussion Panel

Prof. Eng Kiong YEOH

<To be updated>

Dr. Derrick AU

<u>Derrick Au</u> is the Director of the CUHK Centre for Bioethics at the Chinese University of Hong Kong and current Chairman of the Bioethics Course Committee in CUHK Faculty of Medicine. Dr Au received medical education at Brown University and postgraduate training in Hong Kong. He served in medical geriatric and rehabilitation services for two decades before taking up management positions in the Hospital Authority (HA), including Director of Quality & Safety. In public service Dr Au has served as member of committees in the Medical Council of Hong Kong (2012-2019), Chairman of the HA Clinical Ethics Committee (2017-2020), the HKSAR Steering Committee on Genomic Medicine (2017-2021) and current Convenor of the Ethics Advisory Committee of the Hong Kong Genome Institute.

Dr. Julie PAVLIN

Julie Pavlin is the Director of the Board on Global Health at the National Academies of Sciences, Engineering, and Medicine where she coordinates analyses of health developments beyond US borders, and areas of international health investment that promote global well-being, security, and economic development. Prior to this position, she was a Research Area Director at the Infectious Disease Clinical Research Program, and the Deputy Director of the Armed Forces Health Surveillance Center. She is a retired Colonel in the US Army with previous assignments including the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand, the Walter Reed Army Institute of Research, and the US Army Medical Research Institute for Infectious Diseases. She concentrated most of her time with the Department of Defense in the design of real-time disease surveillance systems and was a co-founder of the International Society for Disease Surveillance. Dr. Pavlin received her AB from Cornell University, MD from Loyola University, MPH from Harvard University and PhD in Emerging Infectious Diseases at the Uniformed Services University.

Distinguished Guests

Prof. Rocky TUAN

<u>Rocky Tuan</u> began his term as the eighth Vice-Chancellor and President of The Chinese University of Hong Kong (CUHK) on 1 January 2018. Born and raised in Hong Kong, he pursued further studies in the USA and received his PhD in Life Sciences in 1977 from the Rockefeller University in New York.

As an internationally renowned biomedical scientist specializing in musculoskeletal biology and tissue regeneration, Professor Tuan has authored >550 research publications. His work covers both basic science and engineering, as well as translational and clinical applications. Prior to joining CUHK in 2016 as a distinguished visiting professor and the founding director of the Institute for Tissue Engineering and Regenerative Medicine, he was distinguished professor of orthopaedic surgery and director of the Center for Cellular and Molecular Engineering in the University of Pittsburgh School of Medicine.

Prof. Tuan was elected to the fellowships of the American Institute for Medical and Biological Engineering (2000), National Academy of Inventors (2017), the Chinese Association of Inventions (2018), the American Association for Anatomy (2019), the Orthopaedic Research Society (2021), and the Tissue Engineering and Regenerative Medicine International Society (2021) for his accomplishments in innovation and translational research that bring significant impact on society.

Dr. Victor DZAU

<u>Victor Dzau</u> is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Vice Chair of the National Research Council. Dr. Dzau is Chancellor Emeritus and James B. Duke Distinguished Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System.

Dr. Dzau is an internationally acclaimed physician scientist and leader whose work has improved health and medicine in the United States and globally. His seminal work in cardiovascular medicine and genetics laid the foundation for the development of the class of lifesaving drugs known as ACE inhibitors, used globally to treat hypertension and heart failure. Dr. Dzau is also a leader in health and heath policy. At the NAM, he has led important initiatives such as Vital Directions for Health and Health Care, the Action Collaborative on Countering the US Opioid Epidemic, and the Action Collaborative on Clinician Well-Being and Resilience.

Dr. Dzau has served as a member of the Advisory Committee to the Director of the National Institutes of Health (NIH), chaired the NIH Cardiovascular Disease Advisory Committee and NHLBI Cardiovascular Progenitor Cell Biology Consortium. Currently, he chairs the Cardiovascular Progenitor Cell Translational Consortium. He is a member of the Health and Biomedical Sciences International Advisory Council of Singapore, as well as a board member of the Imperial College Health Partners, UK and the Gairdner Foundation.

Last Update on 25 January 2022